Ironwood Pharmaceuticals (IRWD) Retained Earnings (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Retained Earnings across 17 years of filings, most recently posting -$1.6 billion for Q2 2026.

• In Q2 2026, Retained Earnings rose 7.59% year-over-year to -$1.6 billion; the TTM figure through Jun 2026 stood at -$1.6 billion (up 7.59% YoY), while the FY2025 annual figure was -$1.7 billion, up 1.41% from the prior year.
• Retained Earnings came in at -$1.6 billion for Q2 2026 at Ironwood Pharmaceuticals, up from -$1.6 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$650.7 million in Q1 2023 to a low of -$1.7 billion in Q1 2025.
• Average Retained Earnings over 5 years is -$1.4 billion, with a median of -$1.7 billion recorded in 2023.
• Year-over-year, Retained Earnings jumped 41.62% in 2022 and slumped 161.7% in 2024.
• Over 5 years, Retained Earnings stood at -$696.4 million in 2022, then slumped by 143.92% to -$1.7 billion in 2023, then gained by 0.05% to -$1.7 billion in 2024, then climbed by 1.41% to -$1.7 billion in 2025, then rose by 5.5% to -$1.6 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$1.6 billion in Q2 2026, -$1.6 billion in Q1 2026, and -$1.7 billion in Q4 2025.